citalopram has been researched along with Hypertrophy, Right Ventricular in 2 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Hypertrophy, Right Ventricular: Enlargement of the RIGHT VENTRICLE of the heart. This increase in ventricular mass is often attributed to PULMONARY HYPERTENSION and is a contributor to cardiovascular morbidity and mortality.
| Excerpt | Relevance | Reference |
|---|---|---|
| " During exposure to hypoxia (10% O2 for 2 weeks), the animals received one of the specific 5-HTT inhibitors citalopram and fluoxetine (10 mg/kg/day), the selective 5-HT1B/1D receptor antagonist GR127935 (2 and 10 mg/kg/day), or the 5-HT2A receptor antagonist ketanserin (2 mg/kg/day)." | 3.72 | Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. ( Adnot, S; Eddahibi, S; Hamon, M; Marcos, E; Nosjean, A; Pham, MH; Raffestin, B, 2003) |
| "Hypoxia-induced increases in right ventricular hypertrophy and pulmonary vascular remodeling were also potentiated in the 5-HTT+ mice." | 1.32 | Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. ( Colston, J; Dempsie, Y; Deuchar, GA; Harmar, A; Hicks, MN; Loughlin, L; MacLean, MR; Morecroft, I; Nilsen, M; Shen, S; Sheward, J, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marcos, E | 1 |
| Adnot, S | 1 |
| Pham, MH | 1 |
| Nosjean, A | 1 |
| Raffestin, B | 1 |
| Hamon, M | 1 |
| Eddahibi, S | 1 |
| MacLean, MR | 1 |
| Deuchar, GA | 1 |
| Hicks, MN | 1 |
| Morecroft, I | 1 |
| Shen, S | 1 |
| Sheward, J | 1 |
| Colston, J | 1 |
| Loughlin, L | 1 |
| Nilsen, M | 1 |
| Dempsie, Y | 1 |
| Harmar, A | 1 |
2 other studies available for citalopram and Hypertrophy, Right Ventricular
| Article | Year |
|---|---|
Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension.
Topics: Analysis of Variance; Animals; Carrier Proteins; Chronic Disease; Citalopram; Disease Models, Animal | 2003 |
Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension.
Topics: Animals; Binding Sites; Carrier Proteins; Citalopram; Gene Expression; Hemodynamics; Hypertension, P | 2004 |